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Guideline on the Assessment
of Cardiovascular RiskWe applaud the effort of the ACC/AHA Risk Assessment Work
Group to develop novel equations to estimate the risk of a ﬁrst hard
atherosclerotic cardiovascular event using data from broadly
representative cohorts of the U.S. population (1). However, we are
concerned that they may not adequately predict risk in patients
with inﬂammatory forms of arthritis, such as rheumatoid arthritis,
psoriatic arthritis, and ankylosing spondylitis. Considerable epide-
miological evidence supports the notion that inﬂammatory arthritis
is an independent risk factor for both myocardial infarction and
stroke (2–4). In addition, a recent assessment of the performance
of cardiovascular risk algorithms in an early rheumatoid arthritis
inception cohort demonstrated that the Framingham Global
Risk Score, SCORE, and the Reynolds Risk Score all under-
estimated 10-year risk (5).
Although it is brieﬂy mentioned in the 2013 Blood Cholesterol
Guideline (6), we want to highlight the increased risk of cardio-
vascular disease in those with inﬂammatory arthritis and emphasize
that until well-validated risk scores are developed for this popula-
tion, using those derived from the general population will likely
underestimate risk.*Bruce Andrus, MD, MS
Diane Lacaille, MD, MHSc
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on the Assessment of
Cardiovascular RiskThe American College of Cardiology Foundation/American Heart
Association (ACCF/AHA) welcomes letters to inform its ongoing
work and encourages such correspondence about its guidelines.
Because the ACCF/AHA guideline development process is
rigorous and involves several layers of review by the writing com-
mittee, external peer reviewers, and participating organizations in
the document, it cannot respond to each issue raised after a guide-
line has been published. The information, however, is forwarded to
the Writing Committee chair and oversight Task Force for review.
If any issue is deemed by the ACCF/AHA to affect patient safety,
it will be considered immediately. Otherwise, the information will
be considered during the next update or revision of the guideline.The ACC Guidelines Committee
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